A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Fuse Medical, Inc.
FZMD
$2M
Mkt Cap
$0.02
+0.00%
Fuse Medical, Inc. (FZMD) has a current P/E ratio of 0.5, compared to its historical median P/E of 6.9. The stock is currently considered Fair based on its historical valuation range.
Fuse Medical, Inc. (FZMD) has a 5-year average return on invested capital (ROIC) of -11.1%. This is below average and may indicate limited pricing power.
Fuse Medical, Inc. (FZMD) has a market capitalization of $1M. It is classified as a small-cap stock.
Fuse Medical, Inc. (FZMD) does not currently pay a regular dividend.
Based on historical P/E analysis, Fuse Medical, Inc. (FZMD) appears fair. The current P/E of 0.5 is 93% below its historical median of 6.9. The estimated fair value CAGR (P/E method) is 5.8%.
Fuse Medical, Inc. (FZMD) operates in the Wholesale-Medical, Dental & Hospital Equipment & Supplies industry, within the Consumer Cyclical sector.
Fuse Medical, Inc. (FZMD) reported annual revenue of $19 million in its most recent fiscal year, based on SEC EDGAR filings.
We are a manufacturer and national distributor of medical devices in the United States. We provide a broad portfolio of orthopedic implants including: Foot and Ankle: internal and external fixation products; Orthopedics: upper and lower extremity plating and total joint reconstruction implants; Sports Medicine: soft tissue fixation and augmentation for sports medicine procedures; Spine: full spinal implants for trauma, degenerative disc disease, and deformity indications (collectively, we refer to these bulleted products as “Orthopedic Implants”). We also provide a wide array of osteo-biologics and regenerative products, which include human allografts, tendons, synthetic skin and bone substitute materials, and regenerative tissues, which we refer to as (“Biologics”). All of our medical devices are approved by the U.S.
| Metric | TTM | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Revenue | 18M | 19M | 20M | 21M | 23M | 26M |
| Net Income | 3.6M | 3.1M | -1.6M | -1.4M | -3.3M | 4.0M |
| EPS | $0.05 | $0.04 | $-0.02 | $-0.02 | $-0.05 | $0.05 |
| Free Cash Flow | 0 | 35K | -1.8M | 216K | -20K | 2.4M |
| ROIC | -1.2% | -4.1% | -12.0% | -5.9% | -23.7% | -9.8% |
| Gross Margin | 64.9% | 61.9% | 58.5% | 59.4% | 48.6% | 49.3% |
| Debt/Equity | 0.00 | -7.07 | -0.77 | -0.17 | -0.12 | 0.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -240K | -815K | -2.2M | -1.0M | -4.3M | -2.0M |
| Operating Margin | -1.3% | -4.4% | -10.8% | -4.8% | -19.0% | -7.4% |
| ROE | 0.0% | - | - | - | - | 269.8% |
| Shares Outstanding | 74M | 77M | 79M | 72M | 66M | 79M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.1M | 941K | 1.7M | 26M | 26M | 26M | 23M | 21M | 20M | 19M | 18M |
| Gross Margin | 80.8% | 48.4% | 60.4% | 56.1% | 44.8% | 49.3% | 48.6% | 59.4% | 58.5% | 61.9% | 64.9% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | 420K | 1.5M | 1.8M | 4.2M | 5.3M | 8.5M | 8.5M | 6.5M | 7.0M | 6.5M | 6.7M |
| EBIT | 436K | -1.3M | -794K | 3.2M | 859K | -2.0M | -4.3M | -1.0M | -2.2M | -815K | -240K |
| Op. Margin | 41.2% | -141.8% | -47.4% | 12.3% | 3.3% | -7.4% | -19.0% | -4.8% | -10.8% | -4.4% | -1.3% |
| Net Income | 435K | -1.4M | -802K | 3.0M | 700K | 4.0M | -3.3M | -1.4M | -1.6M | 3.1M | 3.6M |
| Net Margin | 41.1% | -149.3% | -47.8% | 11.8% | 2.6% | 15.0% | -14.5% | -6.7% | -7.8% | 16.6% | 19.7% |
| Non-Recurring | 0 | 0 | -2K | 0 | 5K | 0 | 932K | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||
| ROIC | 183.6% | N/M | N/M | 33.9% | 4.2% | -9.8% | -23.7% | -5.9% | -12.0% | -4.1% | -1.2% |
| ROE | 1502.7% | -934.7% | -16170.0% | 28.5% | N/A | 269.8% | N/A | N/A | N/A | N/A | 0.0% |
| ROA | 161.1% | -504.2% | -184.3% | 15.4% | 3.6% | 17.8% | -18.0% | -8.2% | -8.7% | 16.3% | 18.8% |
| Cash Flow | |||||||||||
| Op. Cash Flow | 320K | -1.2M | -375K | 2.8M | 1.6M | 2.5M | -5K | 237K | -1.8M | 35K | -404K |
| Free Cash Flow | 318K | -1.2M | -383K | 2.8M | 1.6M | 2.4M | -20K | 216K | -1.8M | 35K | 0 |
| Owner Earnings | 319K | -1.2M | -818K | 2.7M | 1.5M | 1.6M | -739K | -421K | -2.1M | -125K | -487K |
| CapEx | 2K | 61K | 8K | 8K | 20K | 42K | 15K | 21K | 21K | 0 | 0 |
| Maint. CapEx | 0 | 13K | 25K | 19K | 15K | 50K | 107K | 104K | 68K | 137K | 59K |
| Growth CapEx | 1K | 48K | 0 | 0 | 6K | 0 | 0 | 0 | 0 | N/A | 0 |
| D&A | 0 | 13K | 25K | 19K | 15K | 50K | 107K | 104K | 68K | 137K | 59K |
| CapEx/OCF | N/A | N/A | N/A | N/A | 1.3% | 1.7% | N/A | 8.8% | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | N/A | N/A | 418K | 63K | 43K | 835K | 628K | 553K | 258K | 23K | 23K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 500K | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | 135K | -75K | 66K | -1.3M | -1.3M | -1.5M | -2.0M | -2.0M | 1.5M | 1.9M | -157K |
| Cash & Equiv. | 12K | 68K | 8K | 778K | 805K | 844K | 1.1M | 1.2M | 553K | 148K | 507K |
| Long-Term Debt | 60K | 60K | 100K | N/A | N/A | N/A | N/A | 200K | 200K | 200K | 200K |
| Debt/Equity | 1.57 | 0.30 | 16.69 | 0.03 | -0.04 | 0.10 | -0.12 | -0.17 | -0.77 | -7.07 | 0.00 |
| Interest Coverage | 651.8 | -18.6 | -111.7 | 21.5 | 5.3 | -14.6 | -35.8 | -10.8 | -28.1 | -4.8 | -4.8 |
| Equity | 102K | 199K | 5K | 11M | -8.0M | 1.5M | -1.2M | -2.1M | -3.4M | -311K | -232K |
| Total Assets | 535K | 546K | 435K | 20M | 19M | 22M | 18M | 17M | 18M | 20M | 19M |
| Total Liabilities | 433K | 347K | 430K | 9.0M | 27M | 21M | 20M | 20M | 22M | 20M | 20M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | 1.3M | 1.2M | 1.1M | 1.3M | 1.2M | 1.1M |
| Retained Earnings | -3.4M | -1.5M | -2.3M | -2.9M | N/A | 721K | -2.6M | -4.0M | -5.6M | -2.5M | -2.4M |
| Working Capital | 161K | 147K | 76K | 9.8M | 10M | 10M | 6.3M | 5.4M | 2.9M | 1.4M | 754K |
| Current Assets | 534K | 494K | 406K | 19M | 18M | 17M | 14M | 13M | 13M | 14M | 13M |
| Current Liabilities | 373K | 347K | 330K | 9.0M | 8.0M | 7.1M | 8.0M | 7.2M | 9.9M | 12M | 12M |
| Per Share Data | |||||||||||
| EPS | 2.21 | -0.37 | -0.13 | 0.33 | 0.04 | 0.05 | -0.05 | -0.02 | -0.02 | 0.04 | 0.05 |
| Owner EPS | 0.80 | -0.31 | -0.05 | 0.04 | 0.02 | 0.02 | -0.01 | -0.01 | -0.03 | -0.00 | -0.01 |
| Book Value | 0.26 | 0.05 | 0.00 | 0.16 | -0.11 | 0.02 | -0.02 | -0.03 | -0.04 | -0.00 | -0.00 |
| Cash Flow/Share | 0.80 | -0.31 | -0.02 | 0.04 | 0.02 | 0.03 | -0.00 | 0.00 | -0.02 | 0.00 | 0.05 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.4M | 3.8M | 15.9M | 65.9M | 74.6M | 79.2M | 66.3M | 71.6M | 79.4M | 77.5M | 73.9M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | 0.5 | 37.5 | 10.0 | N/A | N/A | N/A | 3.8 | 0.4 |
| P/FCF | N/A | N/A | N/A | 3.6 | 70.6 | 16.2 | N/A | 63.0 | N/A | 333.9 | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 298.5 | 0.9 | N/A | 27.0 | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | 1.5 | 0.4 | 2.3 | 2.8 | 1.3 | 0.8 | 1.0 | 0.9 | 0.1 |
| FCF Yield | N/A | N/A | -25.9% | 28.1% | 1.4% | 6.2% | -0.3% | 1.6% | -8.1% | 0.3% | N/A |
| Market Cap | 0 | 0 | 1.5M | 9.9M | 112M | 40M | 6.6M | 14M | 22M | 12M | 1.5M |
| Avg. Price | 0.00 | 0.00 | 0.40 | 0.14 | 0.82 | 0.94 | 0.47 | 0.23 | 0.25 | 0.21 | 0.02 |
| Year-End Price | 0.00 | 0.00 | 0.24 | 0.15 | 1.50 | 0.50 | 0.10 | 0.19 | 0.28 | 0.15 | 0.02 |
Fuse Medical, Inc. passes 4 of 9 quality checks, suggesting mixed fundamentals.
Fuse Medical, Inc. trades at 0.5x trailing earnings, compared to its 15-year median P/E of 6.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 44.5x vs a median of 39.6x. The company's 5-year average gross margin is 55.5%. At current prices, the estimated annualized return to fair value is -42.2%.
Fuse Medical, Inc. (FZMD) has a net profit margin of 16.6%. This is a healthy margin.
Fuse Medical, Inc. (FZMD) generated $35 thousand in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Fuse Medical, Inc. (FZMD) reported earnings per share (EPS) of $0.04 in its most recent fiscal year.
Fuse Medical, Inc. (FZMD) has a 5-year average gross margin of 55.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 10 years of financial data for Fuse Medical, Inc. (FZMD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Fuse Medical, Inc. (FZMD) has a book value per share of $-0.00, based on its most recent annual SEC filing.